Integrated genomic and AI pathology biomarkers to guide high-risk prostate cancer treatment
Official title: Integrated Clinical-Grade genomic and pathology AI biomarkers for high-risk prostate cancer
Funded at University of Wisconsin-Madison · NIH-11395376 · Data updated 2026-11-12
A prostate cancer research project tests how genomic and AI-based pathology tools can help tailor who should receive added ARSI therapy with standard radiotherapy and hormone treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | August 18, 2025 |
| Project end | July 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $564,717 |
| NIH project number | 5R01CA299863-02 |
| Project ID | NIH-11395376 on NIH RePORTER |
Who could benefit from this research
✓Could help
Men with high-risk localized prostate cancer being considered for RT and ADT, who would be evaluated for ARSI addition.
✕Less likely to help
Patients unlikely to benefit from ARSI augmentation or who have contraindications to ARSI therapy.
What this research studies
This project combines genomic classifier data with advanced AI pathology insights to better predict which high-risk prostate cancer patients will benefit from adding ARSI therapy to RT and ADT. By comparing genomic and AI-based risk stratification against each other, the team aims to identify who gains the most from intensified treatment. The study builds on prior evidence that these classifiers are valid in clinical practice and seeks to determine whether their integration improves decision-making. The goal is to maximize treatment benefit while reducing unnecessary toxicity and cost for patients.
Why it matters
Potential benefit: If successful, patients could receive more personalized therapy that improves outcomes and minimizes side effects and expense.
How similar studies have gone: Previous studies validated the classifiers and supported their use in guidelines; this study tests their combined predictive power.
Where this research is happening
-
University of Wisconsin-Madison
Madison, United States Active
Researchers
- Principal investigator: Zhao, Shuang — University of Wisconsin-Madison
- Study coordinator: Zhao, Shuang
Related research
Other NIH-funded projects on the same topics.
-
Overcoming Resistance to AR-Targeted Therapy in High-Risk Prostate Cancer
Researchers are studying why some high-risk prostate cancers stop responding to AR pathway inhibitors and trying new strategies to improve outcomes for men with aggressive, localized disease.
-
Tumor environment players in advanced prostate cancer spread
Researchers are studying how the tissue around prostate tumors helps cancer spread, in men with high-risk disease.
-
Mitochondrial changes in high-risk prostate cancer
This project looks at changes in mitochondrial DNA and cell energy systems in men, especially African American men, with high‑risk prostate cancer to find markers that predict who will develop aggressive disease.
-
Understanding mitochondrial changes in high-risk prostate cancer
This study is looking at how changes in mitochondrial DNA might affect prostate cancer in African American men, who are more likely to face serious cases, with the hope of finding ways to predict and improve treatment for those at risk.
-
How high-risk prostate tumors and nearby cells kick off cancer spread
This project looks at how high-risk prostate tumors and the immune and support cells around them start to spread by using advanced scans and detailed analysis of removed prostate tissue.
-
Blocking stromal signals to make androgen-blocking treatment work better for high-risk prostate cancer
Researchers are trying to improve outcomes for people with high-risk localized prostate cancer by blocking signals from nearby stromal cells so androgen-blocking drugs work more fully.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.